ETF Holdings Breakdown of BEAM

BEAM institutional holdings

The adjusted close for BEAM on 2025-11-12 was 21.87

The following institutional investment holdings of BEAM have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	66,000	USD 1,443,420 -2.8%	21.87
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,953 -0.3%	USD 217,672 -3.1%	21.87
2025-11-12	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	121,886	USD 2,665,647	21.87
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	65,073	USD 1,423,147	21.87
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	65,073 0.3%	USD 1,423,147 -2.5%	21.87
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	672	USD 14,697 -2.8%	21.87
Total =		328,657	USD 7,187,730

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with BEAM

Beam Therapeutics (NASDAQ:BEAM) Earns “Buy” Rating from HC Wainwright

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 249.19% from the company’s previous close. A number […] - 2025-09-17 02:46:44

Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a hold rating to a sell rating in a report published on Sunday. BEAM has been the topic of several other reports. Barclays lowered their price objective on shares of Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating […] - 2025-09-15 04:42:44

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Wall Street Zen

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday. Several other equities analysts have also commented on BEAM. Cantor Fitzgerald raised Beam Therapeutics to a “strong-buy” rating in a report on Monday, July […] - 2025-09-08 03:02:55

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of “Buy” from Brokerages

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been assigned a consensus rating of “Buy” from the fourteen research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and three have assigned a strong buy rating to the […] - 2025-08-07 02:38:51

Victory Capital Management Inc. Has $207,000 Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Victory Capital Management Inc. boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 18.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,612 shares of the company’s stock after purchasing an additional 1,618 shares during the period. Victory Capital […] - 2025-08-04 05:14:52

Bank of New York Mellon Corp Boosts Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Bank of New York Mellon Corp increased its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 14.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 318,026 shares of the company’s stock after buying an additional […] - 2025-07-24 04:27:08

Arizona State Retirement System Boosts Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Arizona State Retirement System raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 25.6% in the 1st quarter, Holdings Channel reports. The fund owned 25,534 shares of the company’s stock after purchasing an additional 5,197 shares during the period. Arizona State Retirement System’s holdings in Beam Therapeutics were worth $499,000 as of […] - 2025-07-22 07:42:58

Arizona State Retirement System Has $499,000 Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Arizona State Retirement System boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 25.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 25,534 shares of the company’s stock after purchasing an additional 5,197 shares during the period. Arizona State Retirement System’s holdings in Beam […] - 2025-07-22 06:57:02

D.A. Davidson & CO. Has $1.38 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

D.A. Davidson & CO. boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 37.8% in the 1st quarter, HoldingsChannel reports. The firm owned 70,857 shares of the company’s stock after acquiring an additional 19,448 shares during the period. D.A. Davidson & CO.’s holdings in Beam Therapeutics were worth $1,384,000 as of its […] - 2025-07-09 05:53:15

QRG Capital Management Inc. Sells 870 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

QRG Capital Management Inc. cut its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 5.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,635 shares of the company’s stock after selling 870 shares during the period. QRG […] - 2025-06-24 04:46:59

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of “Buy” by Analysts

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been assigned an average recommendation of “Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the […] - 2025-06-23 04:48:53

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp

Northern Trust Corp boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 7.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 740,506 shares of the company’s stock after acquiring an additional 49,415 shares during the period. Northern Trust […] - 2025-05-14 05:54:50

Stifel Financial Corp Acquires 2,976 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

Stifel Financial Corp boosted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 27.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,662 shares of the company’s stock after acquiring an additional 2,976 shares during the quarter. Stifel Financial Corp’s […] - 2025-05-14 04:56:47

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.8% Following Weak Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) shares traded down 6.8% during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $18.37 and last traded at $18.47. 326,775 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 1,947,803 shares. The stock […] - 2025-05-08 02:42:51

Dimensional Fund Advisors LP Has $38.16 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Dimensional Fund Advisors LP boosted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 24.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,538,398 shares of the company’s stock after purchasing an additional 298,067 shares during the period. Dimensional Fund Advisors […] - 2025-05-05 05:20:53

Beam Therapeutics Inc. (NASDAQ:BEAM) Stake Lifted by Sterling Capital Management LLC

Sterling Capital Management LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 816.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,409 shares of the company’s stock after buying an additional 2,146 shares during the quarter. Sterling Capital Management LLC’s holdings in Beam […] - 2025-04-24 06:31:07

Beam Therapeutics Target of Unusually Large Options Trading (NASDAQ:BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 10,060 put options on the company. This is an increase of approximately 1,089% compared to the typical daily volume of 846 put options. Beam Therapeutics Stock Up 3.9 % Beam Therapeutics stock opened at […] - 2025-04-24 02:30:49

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by LPL Financial LLC

LPL Financial LLC grew its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 5.6% during the fourth quarter, Holdings Channel reports. The firm owned 27,698 shares of the company’s stock after acquiring an additional 1,462 shares during the quarter. LPL Financial LLC’s holdings in Beam Therapeutics were worth $687,000 as of […] - 2025-04-23 04:22:56

Federated Hermes Inc. Decreases Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Federated Hermes Inc. decreased its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 20.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 29,709 shares of the company’s stock after selling 7,792 shares during the quarter. Federated Hermes Inc.’s holdings in Beam Therapeutics were worth $737,000 as of its most recent SEC filing. […] - 2025-04-17 05:16:55

Beam Therapeutics Inc. (NASDAQ:BEAM) Holdings Decreased by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 6.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 176,181 shares of the company’s stock after selling 11,664 shares during the period. Russell Investments Group Ltd.’s holdings in Beam Therapeutics were worth $4,369,000 as of its […] - 2025-04-16 05:06:53

Geode Capital Management LLC Trims Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Geode Capital Management LLC cut its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,804,374 shares of the company’s stock after selling 3,309 shares during the quarter. Geode Capital Management […] - 2025-04-15 05:01:01

JPMorgan Chase & Co. Sells 125,567 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

JPMorgan Chase & Co. lowered its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 19.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 513,671 shares of the company’s stock after selling 125,567 shares during the period. […] - 2025-04-14 04:36:51

Alliancebernstein L.P. Has $5.28 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Alliancebernstein L.P. lifted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 149.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 212,804 shares of the company’s stock after purchasing an additional 127,494 shares during the quarter. Alliancebernstein L.P.’s holdings in […] - 2025-04-13 05:44:47

KLP Kapitalforvaltning AS Makes New Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,400 shares of the company’s stock, valued at approximately $332,000. Other hedge funds and other institutional investors have […] - 2025-04-06 07:35:04

Mitsubishi UFJ Asset Management Co. Ltd. Has $244,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)

Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,613 shares of the company’s stock after selling 995 shares during the period. Mitsubishi UFJ Asset Management Co. […] - 2025-04-04 05:12:58

AlphaQuest LLC Reduces Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

AlphaQuest LLC trimmed its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 92.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,610 shares of the company’s stock after selling 33,583 shares during the period. AlphaQuest LLC’s holdings in Beam Therapeutics […] - 2025-03-20 06:13:05

Beam Therapeutics (NASDAQ:BEAM) Earns Overweight Rating from Cantor Fitzgerald

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. BEAM has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Beam Therapeutics in a […] - 2025-03-14 04:44:57

Analysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) Target Price at $51.00

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been given an average recommendation of “Buy” by the fourteen research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to […] - 2025-03-13 04:06:47

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Scotiabank

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating in a report released on Monday, MarketBeat.com reports. The firm presently has a $40.00 target price on the stock. Scotiabank’s price objective would suggest a potential upside of 51.40% from […] - 2025-03-12 04:41:41

Beam Therapeutics (NASDAQ:BEAM) Earns Buy Rating from HC Wainwright

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 202.80% from the stock’s previous close. Several […] - 2025-03-12 04:41:35

Back to Listing

Disclaimer